Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLINDAPASS clindamycin pharmacokinetic study in cardiac surgery with extracorporeal circulation
2025-521555-23-00Phase 2Authorised
- Sponsor
- CHU de Nantes
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of clindamycin in surgical site infection (SSI) and mediastinitis, sponsored by CHU de Nantes. Primary endpoints: Estimated free plasma clindamycin concentration throughout surgery and Comparison of estimated free plasma clindamycin concentration with Staphylococcus aureus ECOFF. Planned start Apr 2026; status: authorised.
02
Drugs
clindamycin
03
Conditions
surgical site infection (SSI)mediastinitis
Beyond the preview
Go deeper on 2025-521555-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521555-23-00.